Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Interim findings from a study conducted at the Houston Methodist Neurological Institute have shown promising outcomes for patients with Frontotemporal Dementia (FTD) who received a combination treatment of low-dose IL-2 and CTLA4-Ig. The initial group of 5 patients experienced a significant and lasting improvement in the number and function of Tregs, leading to minimal cognitive decline during the study period. The treatment was well-tolerated with no serious side effects reported, and all participants successfully completed the trial. Coya Therapeutics, the biotechnology company behind the study, expressed optimism about the results and intends to further explore the potential of this treatment for neurodegenerative diseases like FTD.